

 Shared health Soins communs Manitoba	M38- KETOROLAC (TORADOL)	
	MEDICATION STANDING ORDER	
Version date: 2023-07-24		Effective date: 2023-09-19 (0700 hrs)

INDICATIONS
<ul style="list-style-type: none"> Moderate to severe pain from an acute illness, injury, or an exacerbation of a chronic condition that is significant enough to require analgesic to facilitate safe and comfortable patient transport

CONTRAINDICATIONS
<ul style="list-style-type: none"> Known / suspected acute coronary syndrome (ACS) Known / suspected intracranial injury or hemorrhage True allergy to ketorolac History of aspirin (ASA) induced asthma or bronchospasm Pregnancy Known renal failure

ROUTE (WORK SCOPE)	INITIAL DOSE	REPEAT DOSE
INTRAMUSCULAR / INTRAVENOUS (PCP & ABOVE)	17 years & older – 30 mg	None
	2 up to 17 years - 0.5 mg/kg (max = 30 mg)	
	12 months up to 2 years - 0.25 mg/kg (max = 15 mg)	
INTRAOSSEOUS (ICP & ABOVE)	17 years & older – 30 mg	
	2 up to 17 years - 0.5 mg/kg (max = 30 mg)	
	12 months up to 2 years - 0.25 mg/kg (max = 15 mg)	

NOTES
1. Ketorolac may have a minor effect on coagulation and bleeding time.

APPROVED BY	
	
Medical Director - Provincial EMS/PT	Associate Medical Director - Provincial EMS/PT

VERSION CHANGES (refer to X08 for change tracking)
<ul style="list-style-type: none"> Revised administration table presents information for scope / route / dose more clearly